maritide glp-1 A GIPR antagonist conjugated to analogs promotes weight loss with improved metabolic parameters in preclinical and phase I settings Once Monthly Weight Loss Drug

March 18, 2025

Metabolic Associated Steatotic Liver Disease has emerged as the leading cause of liver damage worldwide, affecting approximately 25% of the global adult population (American Liver Foundation, 2022)

These medications work best with consistent dosing, and irregular use can worsen rebound symptoms when you resume

Clinical trials show mood-related adverse events occur in a small percentage of users, typically during dose escalation

Diabetic Retinopathy Complications Perhaps counterintuitively, the rapid blood sugar improvements achieved through GLP-1 medications can sometimes lead to temporary worsening of diabetic retinopathy

Initial take-up is reported to be strong, and the company said during its fourth-quarter results update this week that around 50,000 prescriptions are currently being filled each week